Vandetanib as a potential treatment for breast cancer

Bibliography

• World Health Organization. Cancer. 2012. Available from: http://www.who.int/cancer/en/
   Google Scholar
• Normanno N, Morabito A, De Luca A, et al. Target-based therapies in breast cancer: current status and future perspectives. Endocr Relat Cancer 2009;16(3):675-702
   PubMed Web of Science ®Google Scholar
• Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med 2003;9(6):669-76
   PubMed Web of Science ®Google Scholar
• Ferrara N, Kerbel RS. Angiogenesis as a therapeutic target. Nature 2005;438(7070):967-74
   PubMed Web of Science ®Google Scholar
• Kerbel RS. Tumor angiogenesis. N Engl J Med 2008;358(19):2039-49
   PubMed Web of Science ®Google Scholar
• Masuda H, Zhang D, Bartholomeusz C, et al. Role of epidermal growth factor receptor in breast cancer. Breast Cancer Res Treat 2012;136(2):331-45
   PubMed Web of Science ®Google Scholar
• De Luca A, Maiello MR, D’Alessio A, et al. The RAS/RAF/MEK/ERK and the PI3K/AKT signalling pathways: role in cancer pathogenesis and implications for therapeutic approaches. Expert Opin Ther Targets 2012;16(Suppl 2):S17-27
   PubMed Web of Science ®Google Scholar
• Kerbel RS. Strategies for improving the clinical benefit of antiangiogenic drug based therapies for breast cancer. J Mammary Gland Biol Neoplasia 2012;17(3-4):229-39
   PubMed Web of Science ®Google Scholar
• Kumler I, Christiansen OG, Nielsen DL. A systematic review of bevacizumab efficacy in breast cancer. Cancer Treat Rev 2014. [Epub ahead of print]
   Web of Science ®Google Scholar
• Ivy SP, Wick JY, Kaufman BM. An overview of small-molecule inhibitors of VEGFR signaling. Nat Rev Clin Oncol 2009;6(10):569-79
   PubMed Web of Science ®Google Scholar
• Hennequin LF, Stokes ES, Thomas AP, et al. Novel 4-anilinoquinazolines with C-7 basic side chains: design and structure activity relationship of a series of potent, orally active, VEGF receptor tyrosine kinase inhibitors. J Med Chem 2002;45(6):1300-12
   PubMed Web of Science ®Google Scholar
• Wedge SR, Ogilvie DJ, Dukes M, et al. ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration. Cancer Res 2002;62(16):4645-55
   PubMed Web of Science ®Google Scholar
• Carlomagno F, Vitagliano D, Guida T, et al. ZD6474, an orally available inhibitor of KDR tyrosine kinase activity, efficiently blocks oncogenic RET kinases. Cancer Res 2002;62(24):7284-90
   PubMed Web of Science ®Google Scholar
• Carlomagno F, Guida T, Anaganti S, et al. Disease associated mutations at valine 804 in the RET receptor tyrosine kinase confer resistance to selective kinase inhibitors. Oncogene 2004;23(36):6056-63
   PubMed Web of Science ®Google Scholar
• Arao T, Fukumoto H, Takeda M, et al. Small in-frame deletion in the epidermal growth factor receptor as a target for ZD6474. Cancer Res 2004;64(24):9101-4
   PubMed Web of Science ®Google Scholar
• Sarkar S, Mazumdar A, Dash R, et al. ZD6474, a dual tyrosine kinase inhibitor of EGFR and VEGFR-2, inhibits MAPK/ERK and AKT/PI3-K and induces apoptosis in breast cancer cells. Cancer Biol Ther 2010;9(8):592-603
   PubMed Web of Science ®Google Scholar
• Sarkar S, Mazumdar A, Dash R, et al. ZD6474 enhances paclitaxel antiproliferative and apoptotic effects in breast carcinoma cells. J Cell Physiol 2011;226(2):375-84
   PubMed Web of Science ®Google Scholar
• Morabito A, Piccirillo MC, Falasconi F, et al. Vandetanib (ZD6474), a dual inhibitor of vascular endothelial growth factor receptor (VEGFR) and epidermal growth factor receptor (EGFR) tyrosine kinases: current status and future directions. Oncologist 2009;14(4):378-90
   PubMed Web of Science ®Google Scholar
• Arao T, Yanagihara K, Takigahira M, et al. ZD6474 inhibits tumor growth and intraperitoneal dissemination in a highly metastatic orthotopic gastric cancer model. Int J Cancer 2006;118(2):483-9
   PubMed Web of Science ®Google Scholar
• Wu W, Onn A, Isobe T, et al. Targeted therapy of orthotopic human lung cancer by combined vascular endothelial growth factor and epidermal growth factor receptor signaling blockade. Mol Cancer Ther 2007;6(2):471-83
   PubMed Web of Science ®Google Scholar
• Gule MK, Chen Y, Sano D, et al. Targeted therapy of VEGFR2 and EGFR significantly inhibits growth of anaplastic thyroid cancer in an orthotopic murine model. Clin Cancer Res 2011;17(8):2281-91
   PubMed Web of Science ®Google Scholar
• Ciardiello F, Bianco R, Caputo R, et al. Antitumor activity of ZD6474, a vascular endothelial growth factor receptor tyrosine kinase inhibitor, in human cancer cells with acquired resistance to antiepidermal growth factor receptor therapy. Clin Cancer Res 2004;10(2):784-93
   PubMed Web of Science ®Google Scholar
• Taguchi F, Koh Y, Koizumi F, et al. Anticancer effects of ZD6474, a VEGF receptor tyrosine kinase inhibitor, in gefitinib (“Iressa”)-sensitive and resistant xenograft models. Cancer Sci 2004;95(12):984-9
   PubMed Web of Science ®Google Scholar
• Holden SN, Eckhardt SG, Basser R, et al. Clinical evaluation of ZD6474, an orally active inhibitor of VEGF and EGF receptor signaling, in patients with solid, malignant tumors. Ann Oncol 2005;16(8):1391-7
   PubMed Web of Science ®Google Scholar
• Tamura T, Minami H, Yamada Y, et al. A phase I dose-escalation study of ZD6474 in Japanese patients with solid, malignant tumors. J Thorac Oncol 2006;1(9):1002-9
   PubMed Web of Science ®Google Scholar
• Zhang L, Li S, Zhang Y, et al. Pharmacokinetics and tolerability of vandetanib in Chinese patients with solid, malignant tumors: an open-label, phase I, rising multiple-dose study. Clin Ther 2011;33(3):315-27
   PubMed Web of Science ®Google Scholar
• Martin P, Oliver S, Kennedy SJ, et al. Pharmacokinetics of vandetanib: three phase I studies in healthy subjects. Clin Ther 2012;34(1):221-37
   PubMed Web of Science ®Google Scholar
• Heymach JV, Johnson BE, Prager D, et al. Randomized, placebo-controlled phase II study of vandetanib plus docetaxel in previously treated non small-cell lung cancer. J Clin Oncol 2007;25(27):4270-7
   PubMed Web of Science ®Google Scholar
• Weil A, Martin P, Smith R, et al. Pharmacokinetics of vandetanib in subjects with renal or hepatic impairment. Clin Pharmacokinet 2010;49(9):607-18
   PubMed Web of Science ®Google Scholar
• Caprelsa. European Medicines Agency. Summary of product characteristics. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR__Product_Information/human/002315/WC500123555.pdf [Last accessed 30 April 2014]
   Google Scholar
• Caprelsa. US Food and Drug Administration. Prescribing Informations. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/022405s000lbl.pdf [Last accessed 30 April 2014]
   Google Scholar
• Miller KD, Trigo JM, Wheeler C, et al. A multicenter phase II trial of ZD6474, a vascular endothelial growth factor receptor-2 and epidermal growth factor receptor tyrosine kinase inhibitor, in patients with previously treated metastatic breast cancer. Clin Cancer Res 2005;11(9):3369-76
   PubMed Web of Science ®Google Scholar
• Clinical trials.gov. A Randomized, double-blind, placebo-controlled trial investigating the effect of vandetanib on cellular markers of proliferation and apoptosis in invasive breast cancer. Available from: http://clinicaltrials.gov/show/NCT01934335
   Google Scholar
• Bareschino MA, Schettino C, Colantuoni G, et al. The role of antiangiogenetic agents in the treatment of breast cancer. Curr Med Chem 2011;18(33):5022-32
   PubMed Web of Science ®Google Scholar
• Boer K, Lang I, Llombart-Cussac A, et al. Vandetanib with docetaxel as second-line treatment for advanced breast cancer: a double-blind, placebo-controlled, randomized Phase II study. Invest New Drugs 2012;30(2):681-7
   PubMed Web of Science ®Google Scholar
• Kerbel RS, Kamen BA. The anti-angiogenic basis of metronomic chemotherapy. Nat Rev Cancer 2004;4(6):423-36
   PubMed Web of Science ®Google Scholar
• Mayer EL, Isakoff SJ, Klement G, et al. Combination antiangiogenic therapy in advanced breast cancer: a phase 1 trial of vandetanib, a VEGFR inhibitor, and metronomic chemotherapy, with correlative platelet proteomics. Breast Cancer Res Treat 2012;136(1):169-78
   PubMed Web of Science ®Google Scholar
• Fedele P, Calvani N, Marino A, et al. Targeted agents to reverse resistance to endocrine therapy in metastatic breast cancer: where are we now and where are we going? Crit Rev Oncol Hematol 2012;84(2):243-51
   PubMed Web of Science ®Google Scholar
• Clemons M, Cochrane B, Califaretti N. Randomized phase II placebo-controlled trial of fulvestrant plus vandetanib in postmenopausal women with bone only or bone predominant, hormone receptor-positive metastatic breast cancer (MBC): OCOG Zamboney study-NCT00811369. J Clin Oncol 2013;31(Suppl):abstract 574
   Google Scholar
• Clinical trials.gov. A randomized,double-blind,parallel-group,multicentre,Phase II study to evaluate the safety and pharmacological activity of the combination of vandetanib (100 or 300 MG/daily or placebo)with fulvestrant (loading dose)in postmenopausal advanced BC patients. Available from: http://clinicaltrials.gov/ct2/show/NCT00752986
   Google Scholar
• Clinical trials.gov. Randomized Phase II trial of Anastrozole combined with novel agent ZD6474 in the neoadjuvant treatment of postmenopausal patients with hormone receptor-positive breast cancer. Available from: http://clinicaltrials.gov/ct2/show/NCT00481845
   Google Scholar
• Qi WX, Shen Z, Lin F, et al. Incidence and risk of hypertension with vandetanib in cancer patients: a systematic review and meta-analysis of clinical trials. Br J Clin Pharmacol 2013;75(4):919-30
   PubMed Web of Science ®Google Scholar
• Zang J, Wu S, Tang L, et al. Incidence and risk of QTc interval prolongation among cancer patients treated with vandetanib: a systematic review and meta-analysis. PLoS One 2012;7(2):e30353
   PubMed Web of Science ®Google Scholar
• Morabito A, Piccirillo MC, Costanzo R, et al. Vandetanib: an overview of its clinical development in NSCLC and other tumors. Drugs Today (Barc) 2010;46(9):683-98
   PubMed Web of Science ®Google Scholar
• Relf M, LeJeune S, Scott PA, et al. Expression of the angiogenic factors vascular endothelial cell growth factor, acidic and basic fibroblast growth factor, tumor growth factor beta-1, platelet-derived endothelial cell growth factor, placenta growth factor, and pleiotrophin in human primary breast cancer and its relation to angiogenesis. Cancer Res 1997;57(5):963-9
   PubMed Web of Science ®Google Scholar
• Brown LF, Berse B, Jackman RW, et al. Expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in breast cancer. Hum Pathol 1995;26(1):86-91
   PubMed Web of Science ®Google Scholar
• Casanovas O, Hicklin DJ, Bergers G, Hanahan D. Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors. Cancer Cell 2005;8(4):299-309
   PubMed Web of Science ®Google Scholar
• Clinical trials.gov. A Cancer Research UK Phase I Dose Escalation Trial of Oral VEGFR and EGFR Inhibitor, Vandetanib in combination with the oral MEK Inhibitor, Selumetinib (VanSel-1) in Solid Tumours (Dose Escalation) and NSCLC (Expansion Cohort). Available from: http://clinicaltrials.gov/show/NCT01586624
   Google Scholar
• Kummar S, Gutierrez ME, Chen A, et al. Phase I trial of vandetanib and bevacizumab evaluating the VEGF and EGF signal transduction pathways in adults with solid tumours and lymphomas. Eur J Cancer 2011;47(7):997-1005
   PubMed Web of Science ®Google Scholar
• Moreno Garcia V, Basu B, Molife LR, Kaye SB. Combining antiangiogenics to overcome resistance: rationale and clinical experience. Clin Cancer Res 2012;18(14):3750-61
   PubMed Web of Science ®Google Scholar
• Schneider BP, Wang M, Radovich M, et al. Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab in advanced breast cancer: ECOG 2100. J Clin Oncol 2008;26(28):4672-8
   PubMed Web of Science ®Google Scholar
• Sessa C, Guibal A, Del Conte G, Ruegg C. Biomarkers of angiogenesis for the development of antiangiogenic therapies in oncology: tools or decorations? Nat Clin Pract Oncol 2008;5(7):378-91
   PubMedGoogle Scholar
• Denduluri N, Yang SX, Berman AW, et al. Circulating biomarkers of bevacizumab activity in patients with breast cancer. Cancer Biol Ther 2008;7(1):15-20
   PubMed Web of Science ®Google Scholar